---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-015319"
form_type: "8-K"
ticker: "SNGX"
cik: "0000812796"
company_name: "SOLIGENIX, INC."
filed_at: "2022-10-25T23:59:59+00:00"
generated_at: "2026-06-23T01:30:13.073988+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Soligenix forms Psoriasis Medical Advisory Board; Phase 2a study starts December 2022

## Summary
- Formed Medical Advisory Board (MAB) for SGX302 (synthetic hypericin) in mild-to-moderate psoriasis.
- Phase 2a clinical study anticipated to begin in December 2022; FDA previously cleared IND and protocol.
- MAB chaired by Neal Bhatia, MD (Therapeutics Clinical Research, San Diego).
- Previous positive Phase 3 trial of HyBryte (same synthetic hypericin) in CTCL supports psoriasis program.
- Psoriasis affects >7.5 million patients in the U.S.; MAB includes four board-certified dermatologists.

## SEC filing metadata
- accession: 0001558370-22-015319
- form_type: 8-K
- ticker: SNGX
- cik: 0000812796
- company_name: SOLIGENIX, INC.
- filed_at: 2022-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/812796/000155837022015319/0001558370-22-015319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/812796/000155837022015319/tmb-20221025x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-015319
- JSON: https://secwatch.observer/filing/0001558370-22-015319.json
- Plain text: https://secwatch.observer/filing/0001558370-22-015319.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.